These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
384 related items for PubMed ID: 25553976
1. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease. Bangari DS, Ashe KM, Desnick RJ, Maloney C, Lydon J, Piepenhagen P, Budman E, Leonard JP, Cheng SH, Marshall J, Thurberg BL. Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976 [Abstract] [Full Text] [Related]
2. Cardiac manifestations of Fabry disease in G3Stg/GlaKO and GlaKO mouse models-Translation to Fabry disease patients. Kugadas A, Artoni P, Ruangsiriluk W, Zhao M, Boukharov N, Islam R, Volfson D, Derakhchan K. PLoS One; 2024 Mar; 19(5):e0304415. PubMed ID: 38820517 [Abstract] [Full Text] [Related]
3. Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy. Thurberg BL, Rennke H, Colvin RB, Dikman S, Gordon RE, Collins AB, Desnick RJ, O'Callaghan M. Kidney Int; 2002 Dec; 62(6):1933-46. PubMed ID: 12427118 [Abstract] [Full Text] [Related]
4. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Ziegler RJ, Yew NS, Li C, Cherry M, Berthelette P, Romanczuk H, Ioannou YA, Zeidner KM, Desnick RJ, Cheng SH. Hum Gene Ther; 1999 Jul 01; 10(10):1667-82. PubMed ID: 10428212 [Abstract] [Full Text] [Related]
5. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors. Przybylska M, Wu IH, Zhao H, Ziegler RJ, Tousignant JD, Desnick RJ, Scheule RK, Cheng SH, Yew NS. J Gene Med; 2004 Jan 01; 6(1):85-92. PubMed ID: 14716680 [Abstract] [Full Text] [Related]
6. Characterization of small fiber pathology in a mouse model of Fabry disease. Hofmann L, Hose D, Grießhammer A, Blum R, Döring F, Dib-Hajj S, Waxman S, Sommer C, Wischmeyer E, Üçeyler N. Elife; 2018 Oct 17; 7():. PubMed ID: 30328411 [Abstract] [Full Text] [Related]
7. A Phase 2 study of migalastat hydrochloride in females with Fabry disease: selection of population, safety and pharmacodynamic effects. Giugliani R, Waldek S, Germain DP, Nicholls K, Bichet DG, Simosky JK, Bragat AC, Castelli JP, Benjamin ER, Boudes PF. Mol Genet Metab; 2013 May 17; 109(1):86-92. PubMed ID: 23474038 [Abstract] [Full Text] [Related]
8. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease. Sueoka H, Aoki M, Tsukimura T, Togawa T, Sakuraba H. PLoS One; 2015 May 17; 10(12):e0144958. PubMed ID: 26661087 [Abstract] [Full Text] [Related]
9. Normal hearing in alpha-galactosidase A-deficient mice, the mouse model for Fabry disease. Noben-Trauth K, Neely H, Brady RO. Hear Res; 2007 Dec 17; 234(1-2):10-4. PubMed ID: 17933476 [Abstract] [Full Text] [Related]
10. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development. Üçeyler N, Biko L, Hose D, Hofmann L, Sommer C. Mol Pain; 2016 Dec 17; 12():. PubMed ID: 27145802 [Abstract] [Full Text] [Related]
11. Inner ear pathology of alpha-galactosidase A deficient mice, a model of Fabry disease. Sakurai Y, Suzuki R, Yoshida R, Kojima H, Watanabe M, Manome Y, Ohashi T, Eto Y, Moriyama H. Auris Nasus Larynx; 2010 Jun 17; 37(3):274-80. PubMed ID: 19900774 [Abstract] [Full Text] [Related]
12. Enhanced thrombospondin-1 causes dysfunction of vascular endothelial cells derived from Fabry disease-induced pluripotent stem cells. Do HS, Park SW, Im I, Seo D, Yoo HW, Go H, Kim YH, Koh GY, Lee BH, Han YM. EBioMedicine; 2020 Feb 17; 52():102633. PubMed ID: 31981984 [Abstract] [Full Text] [Related]
13. Local and global cerebral blood flow and glucose utilization in the alpha-galactosidase A knockout mouse model of Fabry disease. Itoh Y, Esaki T, Cook M, Qasba P, Shimoji K, Alroy J, Brady RO, Sokoloff L, Moore DF. J Neurochem; 2001 Dec 17; 79(6):1217-24. PubMed ID: 11752062 [Abstract] [Full Text] [Related]
14. Neurophysiological, behavioral and morphological abnormalities in the Fabry knockout mice. Rodrigues LG, Ferraz MJ, Rodrigues D, Pais-Vieira M, Lima D, Brady RO, Sousa MM, Sá-Miranda MC. Neurobiol Dis; 2009 Jan 17; 33(1):48-56. PubMed ID: 18848893 [Abstract] [Full Text] [Related]
15. Anderson-Fabry disease: a multiorgan disease. Tuttolomondo A, Pecoraro R, Simonetta I, Miceli S, Pinto A, Licata G. Curr Pharm Des; 2013 Jan 17; 19(33):5974-96. PubMed ID: 23448451 [Abstract] [Full Text] [Related]
16. Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease. Hofmann L, Karl F, Sommer C, Üçeyler N. PLoS One; 2017 Jan 17; 12(6):e0180601. PubMed ID: 28662189 [Abstract] [Full Text] [Related]
17. Non-clinical evaluation of JR-051 as a biosimilar to agalsidase beta for the treatment of Fabry disease. Morimoto H, Ito Y, Yoden E, Horie M, Tanaka N, Komurasaki Y, Yamamoto R, Mihara K, Minami K, Hirato T. Mol Genet Metab; 2018 Sep 17; 125(1-2):153-160. PubMed ID: 30054149 [Abstract] [Full Text] [Related]
18. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach. Klug K, Spitzel M, Hans C, Klein A, Schottmann NM, Erbacher C, Üçeyler N. Int J Mol Sci; 2023 Oct 21; 24(20):. PubMed ID: 37895103 [Abstract] [Full Text] [Related]
19. The kidney in Fabry's disease. Pisani A, Visciano B, Imbriaco M, Di Nuzzi A, Mancini A, Marchetiello C, Riccio E. Clin Genet; 2014 Oct 21; 86(4):301-9. PubMed ID: 24645664 [Abstract] [Full Text] [Related]
20. Pain related channels are differentially expressed in neuronal and non-neuronal cells of glabrous skin of fabry knockout male mice. Lakomá J, Rimondini R, Donadio V, Liguori R, Caprini M. PLoS One; 2014 Oct 21; 9(10):e108641. PubMed ID: 25337704 [Abstract] [Full Text] [Related] Page: [Next] [New Search]